Catalyst Event

3SBio Inc (1530) · Other

From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)

4/29/2026, 12:00:00 AM

OtherSentiment: Positive

Announced that its SSS68 injection, a dual-target antibody for APRIL/BAFF, received IND approval from China's NMPA for three autoimmune disease indications; high importance estimated due to the significant clinical potential of the dual-target antibody in three indications, expected.

Korean Translation

자체 개발 이중 표적 항체 SSS68 주사제가 중국 NMPA로부터 3개 자가면역질환 적응증에 대한 임상시험계획(IND) 승인을 받을 것으로 보이며, 이는 다중 표적 치료제의 임상적 잠재력을 고려하여 높은 중요도로 평가되어 예상됨.

Related Recent Events

View Full Timeline